Rebus Holdings, Inc. (RBSH)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Oct 22, 2024
Rebus Holdings Company Description
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer.
Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally.
Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Raul Silvestre |
Contact Details
Address: 2629 Townsgate Road Westlake Village, Delaware 91361 United States | |
| Phone | 818 597 7552 |
| Website | rebus-corp.com |
Stock Details
| Ticker Symbol | RBSH |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US75619J1034 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Raul Silvestre Esq. | Chief Executive Officer, Chief Financial Officer, President, Principal Accounting Officer and Director |
| Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor |
| Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board |